loading
Mersana Therapeutics Inc stock is traded at $2.075, with a volume of 1.51M. It is down -5.88% in the last 24 hours and down -0.95% over the past month. Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
See More
Previous Close:
$2.21
Open:
$2.22
24h Volume:
1.51M
Relative Volume:
1.50
Market Cap:
$263.75M
Revenue:
$36.86M
Net Income/Loss:
$-171.67M
P/E Ratio:
-1.0172
EPS:
-2.04
Net Cash Flow:
$-171.05M
1W Performance:
-17.79%
1M Performance:
-0.95%
6M Performance:
-23.81%
1Y Performance:
+34.19%
1-Day Range:
Value
$2.055
$2.29
1-Week Range:
Value
$2.055
$2.83
52-Week Range:
Value
$1.22
$6.2801

Mersana Therapeutics Inc Stock (MRSN) Company Profile

Name
Name
Mersana Therapeutics Inc
Name
Phone
617-498-0020
Name
Address
840 MEMORIAL DRIVE, CAMBRIDGE
Name
Employee
123
Name
Twitter
@MersanaADC
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
MRSN's Discussions on Twitter

Compare MRSN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
MRSN 2.075 263.75M 36.86M -171.67M -171.05M -2.04
VRTX 467.21 119.83B 10.63B -479.80M -1.35B 13.33
REGN 761.02 83.28B 13.85B 4.65B 3.32B 35.06
ARGX 564.61 33.74B 1.86B -40.29M -1.28B -4.16
ALNY 230.30 30.38B 2.09B -332.26M 16.06M -4.14
BNTX 101.69 24.08B 3.30B -501.07M 1.03B 11.54

Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-04-23 Upgrade Citigroup Neutral → Buy
Jul-28-23 Downgrade Robert W. Baird Outperform → Neutral
Jul-27-23 Downgrade BTIG Research Buy → Neutral
Jul-27-23 Downgrade Citigroup Buy → Neutral
Jul-27-23 Downgrade Guggenheim Buy → Neutral
Jul-27-23 Downgrade JP Morgan Neutral → Underweight
Jul-27-23 Downgrade Truist Buy → Hold
Jul-27-23 Downgrade Wedbush Outperform → Neutral
Jun-16-23 Downgrade JP Morgan Overweight → Neutral
Jun-15-23 Initiated Guggenheim Buy
Mar-16-23 Upgrade JP Morgan Neutral → Overweight
Jan-20-23 Initiated Citigroup Buy
Nov-21-22 Initiated Truist Buy
Oct-15-21 Resumed BTIG Research Buy
Aug-30-21 Initiated H.C. Wainwright Buy
Mar-31-21 Initiated Credit Suisse Neutral
Dec-03-20 Initiated Stifel Buy
Sep-29-20 Resumed JP Morgan Neutral
Apr-29-20 Initiated BTIG Research Buy
Jan-21-20 Reiterated H.C. Wainwright Buy
Mar-11-19 Downgrade JP Morgan Neutral → Underweight
Nov-14-18 Upgrade Leerink Partners Mkt Perform → Outperform
May-08-18 Initiated Robert W. Baird Outperform
Mar-19-18 Downgrade JP Morgan Overweight → Neutral
View All

Mersana Therapeutics Inc Stock (MRSN) Latest News

pulisher
04:11 AM

Leerink Partnrs Issues Optimistic Estimate for MRSN Earnings - Defense World

04:11 AM
pulisher
02:06 AM

Wedbush Predicts Stronger Earnings for Mersana Therapeutics - Defense World

02:06 AM
pulisher
Nov 16, 2024

Mersana Therapeutics transferred with Buy rating at Citi - MSN

Nov 16, 2024
pulisher
Nov 16, 2024

MRSN (Mersana Therapeutics) Short-Term Capital Lease Obliga - GuruFocus.com

Nov 16, 2024
pulisher
Nov 15, 2024

Citi bullish on mersana stock ahead of XMT-1660 data catalyst - Investing.com

Nov 15, 2024
pulisher
Nov 15, 2024

Mersana Therapeutics (NASDAQ:MRSN) Coverage Initiated by Analysts at Citigroup - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

MRSN (Mersana Therapeutics) Short-Term Debt : $8.33 Mil (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

MRSN (Mersana Therapeutics) Purchase Of Business : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

MRSN (Mersana Therapeutics) ROE % Adjusted to Book Value : -18.30% (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

MRSN (Mersana Therapeutics) Debt-to-Revenue : 3.52 (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

MRSN (Mersana Therapeutics) Change In Receivables : $-1.57 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

MRSN (Mersana Therapeutics) Change In Prepaid Assets : $5.85 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

MRSN (Mersana Therapeutics) Retained Earnings : $-869.94 Mil (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024
pulisher
Nov 15, 2024

Mersana Therapeutics Provides Business Update and Financial Results for Third Quarter 2024 - Defense World

Nov 15, 2024
pulisher
Nov 15, 2024

MRSN (Mersana Therapeutics) Ending Cash Position : $59.48 Mil (As of Jun. 2024) - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

MRSN (Mersana Therapeutics) Capex-to-Operating-Cash-Flow : 0.00 (As of Jun. 2024) - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

MRSN (Mersana Therapeutics) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

MRSN (Mersana Therapeutics) Other Long-Term Liabilities : $0.63 Mil (As of Jun. 2024) - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

MRSN (Mersana Therapeutics) Long-Term Capital Lease Obligat - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

MRSN (Mersana Therapeutics) Effect of Exchange Rate Changes : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

MRSN (Mersana Therapeutics) Other Stockholders Equity : $-0.00 Mil (As of Jun. 2024) - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

MRSN (Mersana Therapeutics) Issuance of Debt : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

MRSN (Mersana Therapeutics) Net Income From Continuing Operations : $-104.77 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

MRSN (Mersana Therapeutics) Cash Flow from Operations : $-132.56 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Balyasny Asset Management L.P. Acquires New Stake in Mersana The - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 14, 2024
pulisher
Nov 14, 2024

Rivian, Mersana Therapeutics, MicroStrategy (MSTR) and Honest Company Among Strong Movers in Premarket Trades - TopNews India

Nov 14, 2024
pulisher
Nov 14, 2024

Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Nov 14, 2024
pulisher
Nov 13, 2024

Mersana Therapeutics Reports Q3 2024 Financial Results - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail

Nov 13, 2024
pulisher
Nov 13, 2024

FANG Index (FGU25) Quote - The Globe and Mail

Nov 13, 2024
pulisher
Nov 13, 2024

Mersana Therapeutics Shares Climb 23% After 3Q Results Beat Estimates - MarketWatch

Nov 13, 2024
pulisher
Nov 13, 2024

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Mersana Therapeutics (MRSN) Q3 2024 Earnings: EPS Loss of $0.09 Beats Estimates, Revenue Surges to $12.6M - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

Mersana Therapeutics Reports Progress in Cancer Treatments - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

Mersana Therapeutics, Inc. Provides Business Update - Marketscreener.com

Nov 13, 2024
pulisher
Nov 12, 2024

Earnings Preview For Mersana Therapeutics - Benzinga

Nov 12, 2024
pulisher
Nov 11, 2024

Mersana Therapeutics presents new data on XMT-2056 - BioWorld Online

Nov 11, 2024
pulisher
Nov 11, 2024

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $6.00 Consensus Price Target from Brokerages - Defense World

Nov 11, 2024
pulisher
Nov 08, 2024

Is Mersana Therapeutics (NASDAQ:MRSN) Using Debt Sensibly? - Simply Wall St

Nov 08, 2024
pulisher
Nov 08, 2024

Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Target Price at $6.00 - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Mersana Therapeutics (MRSN) to Release Earnings on Wednesday - MarketBeat

Nov 07, 2024
pulisher
Nov 06, 2024

Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024 - GlobeNewswire

Nov 06, 2024
pulisher
Nov 06, 2024

Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024 - GlobeNewswire Inc.

Nov 06, 2024
pulisher
Nov 02, 2024

MRSN (Mersana Therapeutics) Revenue : $29.94 Mil (TTM As of Jun. 2024) - GuruFocus.com

Nov 02, 2024
pulisher
Oct 30, 2024

Mersana Therapeutics exec Bala Mohan sells stock worth $3,579 - Investing.com India

Oct 30, 2024
pulisher
Oct 29, 2024

Mersana Therapeutics exec Bala Mohan sells stock worth $3,579 By Investing.com - Investing.com South Africa

Oct 29, 2024
pulisher
Oct 25, 2024

SG Americas Securities LLC Reduces Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Oct 25, 2024
pulisher
Oct 23, 2024

Mersana Therapeutics Inc’s Market Journey: Closing Weak at 2.05, Down -2.38 - The Dwinnex

Oct 23, 2024
pulisher
Oct 22, 2024

Exchange Traded Concepts LLC Acquires 41,586 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

Oct 22, 2024

Mersana Therapeutics Inc Stock (MRSN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Mersana Therapeutics Inc Stock (MRSN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Bala Mohan
SVP, Chief Development Officer
Oct 28 '24
Sale
1.90
1,884
3,580
54,731
$18.94
price up icon 3.39%
$75.94
price down icon 0.01%
$39.03
price up icon 6.21%
$360.25
price down icon 0.96%
$187.60
price down icon 1.35%
$99.70
price down icon 0.06%
Cap:     |  Volume (24h):